Fig. 1.
Fig. 1. Serum suPAR levels in patients with CDC-defined HIV-1 disease stages A, B, and C. / Each patient is indicated by a circle; ● indicates that the patient died during follow-up. Median values of suPAR within each stage are indicated by horizontal bars. The serum suPAR levels between the clinical stages were significantly different (P < .0001, Kruskal-Wallis test). Proportions of patients who survived were significantly higher in patients with low levels of suPAR (below the median in the respective group) in all 3 CDC stages (χ2test). Stage A, P = .006; stage B, P = .03; stage C, P = .03.

Serum suPAR levels in patients with CDC-defined HIV-1 disease stages A, B, and C.

Each patient is indicated by a circle; ● indicates that the patient died during follow-up. Median values of suPAR within each stage are indicated by horizontal bars. The serum suPAR levels between the clinical stages were significantly different (P < .0001, Kruskal-Wallis test). Proportions of patients who survived were significantly higher in patients with low levels of suPAR (below the median in the respective group) in all 3 CDC stages (χ2test). Stage A, P = .006; stage B, P = .03; stage C, P = .03.

Close Modal

or Create an Account

Close Modal
Close Modal